The survival benefit of conventional adjuvant therapy (chemotherapy and/or radiotherapy) for ESCC patients was small, possibly only effective for ypN2-3 and ypT3-4 disease (9). Here, RAB11B is linked to esophageal squamous cell carcinoma.